 PALO ALTO, Calif., July 8, 2021 PRNewswire -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh Pitt to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers. 